AbbVie acquires Cerevel Therapeutics for $8.7bn [Yahoo! Finance]
Cerevel Therapeutics Holdings, Inc. (CERE)
Company Research
Source: Yahoo! Finance
In December 2023, the companies signed a definitive agreement under which AbbVie agreed to acquire Cerevel for $45 per share in cash. Cerevel focuses on creating therapies to treat neurological and psychiatric disorders. Through this acquisition, AbbVie will bolster its neuroscience portfolio by adding complementary assets from Cerevel's pipeline. AbbVie CEO Robert Michael stated: “AbbVie's acquisition of Cerevel strengthens our foundation in neuroscience and positions us to deliver sustainable long-term performance into the next decade and beyond. “Our new Cerevel colleagues share our commitment to deliver meaningful change for patients living with neurological and psychiatric conditions. We are excited to welcome the talented Cerevel team to AbbVie.” Cerevel's pipeline products are aimed at neurological and psychiatric conditions such as Parkinson's disease, schizophrenia and mood disorders. Emraclidine is an antipsychotic treatment for schizophrenia from Cerevel. Thi
Show less
Read more
Impact Snapshot
Event Time:
CERE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CERE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CERE alerts
High impacting Cerevel Therapeutics Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
CERE
News
- AbbVie Completes Acquisition of Cerevel Therapeutics [Yahoo! Finance]Yahoo! Finance
- The Schall Law Firm Is Performing A Scrutiny Into Cerevel Therapeutics Holdings Inc And Proprietors Of CERE Shares Are Welcomed To EngageAccesswire
- The Schall Law Firm Is Carrying Out An Inquiry Into Cerevel Therapeutics Holdings Inc And Possessors Of CERE Shares Are Requested To Be Part Of ItAccesswire
- The Schall Law Firm Is Undertaking An Investigation Into Cerevel Therapeutics Holdings Inc And Holders Of CERE Shares Are Encouraged To ParticipateAccesswire
CERE
Earnings
- 5/8/24 - Miss
CERE
Sec Filings
- 8/1/24 - Form 25-NSE
- 8/1/24 - Form S-8
- 8/1/24 - Form S-8
- CERE's page on the SEC website